Discontinuation of joint sales of NEOXY® Tape 73.5 mg
transdermal overactive bladder treatment medication

March 17, 2016
Hisamitsu Pharmaceutical Co., Inc.
Asahi Kasei Pharma Corp.

Hisamitsu Pharmaceutical Co., Inc., (Head office: Tosu city, Saga Prefecture, Japan; President & CEO: Hirotaka Nakatomi; hereinafter referred to as Hisamitsu) and Asahi Kasei Pharma Corp. (Head office: Chiyoda-ku, Tokyo, Japan; President: Kazuyoshi Hori; hereinafter referred to as Asahi Kasei) reached agreement to discontinue their joint sales of NEOXY® Tape 73.5 mg, a transdermal overactive bladder treatment medication, on June 26, 2016.

While Hisamitsu and Asahi Kasei have jointly sold NEOXY® Tape 73.5 mg since June 2013, the agreement to discontinue joint sales was reached as a result of discussion between the two companies. Asahi Kasei will discontinue sales within three months from June 26, 2016, when its inventory of NEOXY® Tape 73.5 mg is depleted. After that, Hisamitsu will sell NEOXY® Tape 73.5 mg alone.


Trade name NEOXY® Tape 73.5 mg
Active pharmaceutical ingredient Oxybutynin hydrochloride
Indication Urinary urgency, frequent urination, and urge urinary incontinence caused by overactive bladders
Dose and Administration Usually apply one sheet (73.5 mg of oxybutynin hydrochloride) once a day on the lower abdomen, lower back, or thigh of an adult and replace every 24 hours.
Packaging 70 sheets (1 sheet/pack × 70),
280 sheets (1 sheet/pack × 280)
NHI drug price 194.80 yen/sheet
Date of approval for manufacturing and marketing March 25, 2013
Date of initial marketing in Japan June 27, 2013
Manufactured and distributed by Hisamitsu Pharmaceutical Co., Inc.